Department of Obstetrics and Gynaecology, Medical University of Vienna, Waehringer Guertel 18-20, Vienna, Austria.
Br J Cancer. 2010 Mar 16;102(6):952-6. doi: 10.1038/sj.bjc.6605547. Epub 2010 Feb 16.
To analyse the correlation between pre-treatment plasma fibrinogen levels and clinical-pathological parameters in patients with endometrial cancer and to assess the value of plasma fibrinogen as a prognostic parameter.
Within a retrospective multi-centre study, the records of 436 patients with endometrial cancer were reviewed and pre-treatment plasma fibrinogen levels were correlated with clinical-pathological parameters and patients' survival.
The mean (s.d.) pre-treatment plasma fibrinogen level was 388.9 (102.4) mg per 100 ml. Higher plasma fibrinogen levels were associated with advanced tumour stage (FIGO I vs II vs III and IV, P=0.002), unfavourable histological subtype (endometrioid vs non-endometrioid histology, P=0.03), and higher patients' age (< or =67 years vs >67 years, P=0.04), but not with higher histological grade (G1 vs G2 vs G3, P=0.2). In a multivariate analysis, tumour stage (P<0.001 and P<0.001), histological grade (P=0.009 and P=0.002), patients' age (P=0.001 and P<0.001), and pre-treatment plasma fibrinogen levels (P=0.04 and P=0.02) were associated with disease-free and overall survival, respectively.
Plasma fibrinogen levels can be used as an independent prognostic parameter for the disease-free and overall survival of patients with endometrial cancer.
分析子宫内膜癌患者治疗前血浆纤维蛋白原水平与临床病理参数的相关性，并评估血浆纤维蛋白原作为预后参数的价值。
在一项回顾性多中心研究中，对 436 例子宫内膜癌患者的病历进行了回顾，并将治疗前血浆纤维蛋白原水平与临床病理参数和患者的生存情况进行了相关性分析。
治疗前血浆纤维蛋白原水平的平均值（标准差）为 388.9（102.4）mg/100ml。较高的血浆纤维蛋白原水平与肿瘤分期较高（FIGO I 期与 II 期、III 期和 IV 期相比，P=0.002）、组织学亚型不良（子宫内膜样 vs 非子宫内膜样组织学，P=0.03）和患者年龄较高（≤67 岁与>67 岁相比，P=0.04）相关，但与组织学分级较高（G1 期与 G2 期、G3 期相比，P=0.2）无关。在多变量分析中，肿瘤分期（P<0.001 和 P<0.001）、组织学分级（P=0.009 和 P=0.002）、患者年龄（P=0.001 和 P<0.001）和治疗前血浆纤维蛋白原水平（P=0.04 和 P=0.02）分别与无病生存率和总生存率相关。
血浆纤维蛋白原水平可作为子宫内膜癌患者无病生存率和总生存率的独立预后参数。
